Literature DB >> 1706984

Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

D W Harron1, K L Goa, H D Langtry.   

Abstract

Bopindolol is a nonselective beta-adrenoceptor antagonist [corrected] with partial agonist activity which is used in the treatment of hypertension. The drug is rapidly metabolised to an active hydrolysed form. The antihypertensive effects of bopindolol 0.5 to 4 mg are sustained for more than 24 hours after once daily dosing, and the drug appears similar in efficacy to propranolol, metoprolol, atenolol, pindolol and slow release nifedipine in the treatment of mild to moderate forms of this disease. In limited trials bopindolol has also successfully reduced symptoms in patients with angina pectoris, anxiety and essential tremor. Thus, bopindolol is an effective and well-tolerated beta-adrenoceptor antagonist.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706984     DOI: 10.2165/00003495-199141010-00010

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  55 in total

1.  Haemodynamic effects of atenolol and bopindolol at rest and during isometric exercise. A non-invasive study in healthy volunteers.

Authors:  M S Nieminen; J Rapola; T J Pellinen; L Toivonen
Journal:  Ann Clin Res       Date:  1988

2.  Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension.

Authors:  W Schiess; D Welzel; R Gugler
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Comparison of the acute haemodynamic effects of bopindolol and propranolol at rest and during supine exercise.

Authors:  P Fitscha; W Meisner; B Tiso
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Bopindolol versus metoprolol in hypertension.

Authors:  R F Westerman; C Christensen; A Westheim; A J Donker
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Activity and duration of action of pindolol and alprenolol compared in healthy volunteers.

Authors:  W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

6.  Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

7.  Beta-blockers and psychic stress: a double-blind, placebo-controlled study of bopindolol vs lorazepam and butalbital in surgical patients.

Authors:  S M Chierichetti; G Moise; M Galeone; G Fiorella; R Lazzari
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1985-09

8.  beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

9.  Effect of bopindolol on the circadian blood pressure profile in essential hypertension.

Authors:  L Favre; R Adamec; G Boxho
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

10.  Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol.

Authors:  J Grevel
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.